Janux Therapeutics (JANX) Non Operating Income (2020 - 2025)
Historic Non Operating Income for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $10.9 million.
- Janux Therapeutics' Non Operating Income rose 4053.71% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year increase of 6673.09%. This contributed to the annual value of $29.9 million for FY2024, which is 10327.52% up from last year.
- As of Q3 2025, Janux Therapeutics' Non Operating Income stood at $10.9 million, which was up 4053.71% from $11.3 million recorded in Q2 2025.
- Over the past 5 years, Janux Therapeutics' Non Operating Income peaked at $11.4 million during Q1 2025, and registered a low of $46000.0 during Q2 2021.
- Over the past 5 years, Janux Therapeutics' median Non Operating Income value was $3.7 million (recorded in 2023), while the average stood at $4.6 million.
- Per our database at Business Quant, Janux Therapeutics' Non Operating Income soared by 287432.43% in 2022 and then skyrocketed by 4053.71% in 2025.
- Janux Therapeutics' Non Operating Income (Quarter) stood at $74000.0 in 2021, then soared by 2874.32% to $2.2 million in 2022, then skyrocketed by 98.96% to $4.4 million in 2023, then skyrocketed by 101.1% to $8.8 million in 2024, then grew by 24.21% to $10.9 million in 2025.
- Its Non Operating Income stands at $10.9 million for Q3 2025, versus $11.3 million for Q2 2025 and $11.4 million for Q1 2025.